PMID- 30187105
OWN - NLM
STAT- MEDLINE
DCOM- 20190520
LR  - 20191210
IS  - 1619-7089 (Electronic)
IS  - 1619-7070 (Linking)
VI  - 46
IP  - 1
DP  - 2019 Jan
TI  - (18)F-FDG PET/CT is useful for determining survival outcomes of patients with 
      multiple myeloma classified as stage II and III with the Revised International 
      Staging System.
PG  - 107-115
LID - 10.1007/s00259-018-4114-0 [doi]
AB  - PURPOSE: This study evaluated the prognostic role of (18)F-FDG PET/CT at baseline 
      in patients with newly diagnosed multiple myeloa (MM) and evaluated the 
      prognostic relevance of (18)F-FDG PET/CT for each stage according to the Revised 
      International Staging System (R-ISS). METHOD: We retrospectively analyzed the 
      records of 167 patients with newly diagnosed MM. (18)F-FDG PET/CT was performed 
      prior to induction therapy in patients with newly diagnosed MM. RESULTS: In the 
      total cohort, the presence of more than three hypermetabolic focal lesions (FLs) 
      or extramedullary disease (EMD) on baseline PET/CT was associated with 
      significantly inferior progression-free survival (PFS) and overall survival (OS) 
      than other patients. Because most patients (91%) with EMD had more than three 
      FLs, PET/CT positivity was defined as the presence of more than three FLs or the 
      presence of EMD. In multivariate analyses, PET/CT positivity was an independent 
      predictor of PFS and OS in all patients. Fifty-five patients (46.1%) with R-ISS 
      II were PET/CT-positive at baseline and had significantly shorter PFS and OS. 
      PET/CT positivity was also correlated with poor PFS and OS in patients with R-ISS 
      III. CONCLUSION: (18)F-FDG PET/CT was an independent predictor of survival 
      outcomes in patients with newly diagnosed MM. In addition, performing (18)F- FDG 
      PET/CT at diagnosis may be useful for determining the survival outcomes of MM 
      patients with R-ISS II and III.
FAU - Jung, Sung-Hoon
AU  - Jung SH
AD  - Department of Hematology-Oncology, Chonnam National University Hwasun Hospital, 
      322 Seoyangro, Hwasun, Jeollanamdo, 519-763, Republic of Korea.
FAU - Kwon, Seong Young
AU  - Kwon SY
AD  - Department of Nuclear Medicine, Chonnam National University Hwasun Hospital, 
      Hwasun, Republic of Korea.
FAU - Min, Jung-Joon
AU  - Min JJ
AD  - Department of Nuclear Medicine, Chonnam National University Hwasun Hospital, 
      Hwasun, Republic of Korea.
FAU - Bom, Hee-Seung
AU  - Bom HS
AD  - Department of Nuclear Medicine, Chonnam National University Hwasun Hospital, 
      Hwasun, Republic of Korea.
FAU - Ahn, Seo-Yeon
AU  - Ahn SY
AD  - Department of Hematology-Oncology, Chonnam National University Hwasun Hospital, 
      322 Seoyangro, Hwasun, Jeollanamdo, 519-763, Republic of Korea.
FAU - Jung, Seung-Yeon
AU  - Jung SY
AD  - Department of Hematology-Oncology, Chonnam National University Hwasun Hospital, 
      322 Seoyangro, Hwasun, Jeollanamdo, 519-763, Republic of Korea.
FAU - Lee, Seung-Shin
AU  - Lee SS
AD  - Department of Hematology-Oncology, Wonkwang University Hospital, Iksan, Republic 
      of Korea.
FAU - Park, Moo-Rim
AU  - Park MR
AD  - Department of Hematology-Oncology, Wonkwang University Hospital, Iksan, Republic 
      of Korea.
FAU - Yang, Deok-Hwan
AU  - Yang DH
AD  - Department of Hematology-Oncology, Chonnam National University Hwasun Hospital, 
      322 Seoyangro, Hwasun, Jeollanamdo, 519-763, Republic of Korea.
FAU - Ahn, Jae-Sook
AU  - Ahn JS
AD  - Department of Hematology-Oncology, Chonnam National University Hwasun Hospital, 
      322 Seoyangro, Hwasun, Jeollanamdo, 519-763, Republic of Korea.
FAU - Kim, Hyeoung-Joon
AU  - Kim HJ
AD  - Department of Hematology-Oncology, Chonnam National University Hwasun Hospital, 
      322 Seoyangro, Hwasun, Jeollanamdo, 519-763, Republic of Korea.
FAU - Lee, Je-Jung
AU  - Lee JJ
AD  - Department of Hematology-Oncology, Chonnam National University Hwasun Hospital, 
      322 Seoyangro, Hwasun, Jeollanamdo, 519-763, Republic of Korea. 
      drjejung@chonnam.ac.kr.
LA  - eng
PT  - Evaluation Study
PT  - Journal Article
DEP - 20180905
PL  - Germany
TA  - Eur J Nucl Med Mol Imaging
JT  - European journal of nuclear medicine and molecular imaging
JID - 101140988
RN  - 0 (Radiopharmaceuticals)
RN  - 0Z5B2CJX4D (Fluorodeoxyglucose F18)
SB  - IM
CIN - Eur J Nucl Med Mol Imaging. 2019 May;46(5):1048-1050. PMID: 30770949
MH  - Adult
MH  - Aged
MH  - Female
MH  - Fluorodeoxyglucose F18
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Multiple Myeloma/*diagnostic imaging/pathology
MH  - Neoplasm Staging/standards
MH  - Positron Emission Tomography Computed Tomography/*standards
MH  - Radiopharmaceuticals
MH  - Survival Analysis
OTO - NOTNLM
OT  - Multiple myeloma
OT  - Positron emission tomography
OT  - Prognosis
OT  - Revised International Staging System
EDAT- 2018/09/07 06:00
MHDA- 2019/05/21 06:00
CRDT- 2018/09/07 06:00
PHST- 2018/06/04 00:00 [received]
PHST- 2018/07/27 00:00 [accepted]
PHST- 2018/09/07 06:00 [pubmed]
PHST- 2019/05/21 06:00 [medline]
PHST- 2018/09/07 06:00 [entrez]
AID - 10.1007/s00259-018-4114-0 [pii]
AID - 10.1007/s00259-018-4114-0 [doi]
PST - ppublish
SO  - Eur J Nucl Med Mol Imaging. 2019 Jan;46(1):107-115. doi: 
      10.1007/s00259-018-4114-0. Epub 2018 Sep 5.